Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.
Daniel George, MD
Advertisement
Articles by Daniel George, MD
In this video, Dr. Daniel George discusses CARMENA, which asked if cytoreductive surgery is necessary in the age of active systemic therapy for mRCC.
Advertisement
Latest Updated Articles
Can mRCC Patients Be Spared Debulking Nephrectomy?June 12th 2018
Dr. Daniel George on the Treatment Landscape for RCCJune 11th 2019
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Navigating New Horizons in Neuroendocrine Prostate Cancer
5